Filing Flows › Phathom Pharmaceuticals (PHAT) › Guidance & outlook
Phathom Pharmaceuticals (PHAT) guidance and outlook
Phathom Pharmaceuticals (PHAT) reaffirmed its guidance on Oct 29, 2026: Revenue $310M–$325M for FY2026; Gross margin 80% for FY2026.
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $310M–$325M | reaffirmed |
| Gross margin | FY2026 | 80% | reaffirmed |
From the earnings release filed Oct 29, 2026 (8-K on EDGAR).
Phathom Pharmaceuticals' latest quarter
Phathom Pharmaceuticals, Q3 2026: revenue $84.7M (+71% year over year), operating margin -0.1%, net loss $13.9M, operating cash flow $1.8M. The chart follows the revenue to costs, profit and cash.
Questions
Did Phathom Pharmaceuticals raise or lower its guidance?
Phathom Pharmaceuticals (PHAT) reaffirmed its guidance on Oct 29, 2026: Revenue $310M–$325M for FY2026; Gross margin 80% for FY2026.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.